Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders

Genetic: whole genome sequencing PD Partecipants will be assessed for disease progression: Stadio di Hoehn and Yahr, MDS-UPDRS part III, MOCA test, no motor symptoms, therapy and LID occurrence, Sleep disorders. Partecipants will be subjected to peripheral blood sampling for the purification of DNA, plasma, serum, PBMC and generation of hiPSC. DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate PD genes

"Genetic: whole genome sequencing~AD Partecipants will be assessed for disease progression:~* assessment of cognitive disorders (MMSE, MOCA test, clock test);~* assessment of language disorders;~* current drug therapy (and possible start date of treatment);~* date of onset of cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate AD genes"

"Genetic: whole genome sequencing~ALS/FTD Partecipants will be assessed for disease progression:~* clinical classification according to El Escorial - revised;~* assessment of cognitive disorders (and classification according to Strong criteria, 2017);~* assessment of language disorders;~* ongoing pharmacological therapy (and possible start date of treatment);~* date of onset of motor and cognitive disorders;~* acquisition and assessment of imaging data where present (MRI, CT, PET). DNA of each partecipants we will analysed by whole genome sequencing by next generation sequencing to identify any variant in candidate ALS/FTD genes"